文献速递疼痛医学

鞘内药物输注系统治疗癌痛:前瞻性多中心产品监测登记分析

Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry.
PubMed 文献 · Anesth Analg · 2020-01-01

基于2003年启动的前瞻性多中心登记,监测SynchroMed输注系统在1403例癌痛患者中的表现,患者平均年龄59岁、56.6%为女性。结果支持鞘内药物输注系统作为癌痛安全有效的治疗选择。

要点

  • 鞘内药物输注系统可显著改善癌痛患者6个月和12个月的疼痛评分。
  • 6个月时EuroQol-5D生活质量评分显著改善。
  • 需手术干预的感染发生率为3.2%。

核心结论

  • 鞘内药物输注系统可为癌症患者(即使晚期)提供充分且改善的疼痛控制,同时维持生活质量。
  • 该大规模多中心单组队列结果补充了现有RCT数据,支持鞘内药物输注系统作为癌痛治疗中安全有效、获益风险比良好的选择。

研究设计与样本

  • 前瞻性、长期、多中心(美国、西欧和拉丁美洲)产品监测登记,2003年启动,监测SynchroMed输注系统性能,2013年加入患者报告结局。
  • 截至2017年7月,共纳入并植入1403例癌痛患者,平均年龄59岁(最小13岁/最大93岁),56.6%为女性。

主要发现

  • 最常见癌症类型为肺癌、乳腺癌、结肠/直肠癌、胰腺癌和前列腺癌。
  • 登记随访结束的患者中87%(1141/1311)随访至死亡,4.3%(n=57)因装置取出或治疗中止退出,其余113例(8.6%)因转诊、失访和中心关闭等原因终止。
  • 需手术干预的感染(装置取出、更换、囊袋修正、冲洗和清创等)发生率为3.2%。

关键数值与推荐

  • 需手术干预的感染发生率:3.2%。

临床怎么用

  • 对于癌痛患者,可考虑鞘内药物输注系统以改善疼痛控制和生活质量。
  • 应用时需关注需手术干预的感染风险(3.2%)。

局限性

  • 为单组队列登记,非随机对照设计。
  • 部分结局数据样本量较小(如12个月疼痛评分n=55,6个月EuroQol-5D n=41)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety and efficacy of intrathecal drug delivery systems (IDDSs) for the treatment of cancer-related pain have been demonstrated in randomized controlled clinical trials (RCTs). Despite positive evidence for this therapy, IDDS remains underutilized to treat cancer pain. Real-world registry data augment existing safety and effectiveness data and are presented here to broaden awareness of this therapeutic option, needed for adequate cancer-related pain treatment, and as a viable tool addressing concerns with systemic opioid use. METHODS: This prospective, long-term, multicenter (United States, Western Europe, and Latin America) registry started in 2003 to monitor the performance of SynchroMed Infusion Systems. Patient-reported outcomes were added in 2013. Before data acquisition, all sites obtained Ethics Committee/Institutional Review Board approval and written patient consent. The study was registered (NCT01524276 at clinicaltrials.gov) before patients were enrolled. Patients who provided informed consent were enrolled in the registry at initial IDDS implant or replacement. RESULTS: Through July 2017, 1403 patients with cancer pain were enrolled and implanted. The average (minimum/maximum) age of patients was 59 years (13/93 years), with 56.6% female. The most frequent cancer types were lung, breast, colon/rectal, pancreatic, and prostate. The majority of patients whose registry follow-up ended (87%; 1141/1311) were followed through death, with 4.3% (n = 57) exiting due to device explant or therapy discontinuation; the remaining 113 (8.6%) discontinued for reasons such as transfer of care, lost to follow-up, and site closure. Pain scores within the cohort of patients providing baseline and follow-up data improved significantly at 6 (P = .0007; n = 103) and 12 (P = .0026; n = 55) months compared to baseline, with EuroQol with 5 dimensions (EuroQol-5D) scores showing significant improvement at 6 months (P = .0016; n = 41). Infection requiring surgical intervention (IDDS explant, replacement, pocket revision, irrigation and debridement, etc) was reported in 3.2% of patients. CONCLUSIONS: Adequate and improved pain control in patients with cancer, even in advanced stages, with concurrent quality of life maintenance is attainable. Results from this large-scale, multicenter, single-group cohort supplement existing RCT data that support IDDS as a safe and effective therapeutic option with a positive benefit-risk ratio in the treatment of cancer pain.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Stearns LM, Abd-Elsayed A, Perruchoud C, et al. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry. Anesth Analg. 2020. PMID: 31567325. doi:10.1213/ANE.0000000000004425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。